demonstrated that the PLK1 inhibitor BI6727 reduced the viability of CCNE1-expanded OC cells, increased their sensitivity to paclitaxel, and induced apoptosis in cancer cells when combined with paclitaxel. Here, PLK1 is linked to cancer.